Myths vs facts: CYP2C19 and weight loss

The claim that CYP2C19 variants directly influence weight loss is largely a myth. CYP2C19 is a liver enzyme primarily involved in drug metabolism (e.g., clopidogrel, proton pump inhibitors). There is no strong human evidence linking CYP2C19 polymorphisms to body weight regulation, fat oxidation, or weight loss success. Some exploratory studies have suggested weak associations with omega-3 fatty acid metabolism or resting energy expenditure, but these findings are inconsistent, small in effect size, and not replicated. Direct-to-consumer DNA tests that market CYP2C19 as a 'weight loss gene' overstate the science. Weight loss is multifactorial, driven by energy balance, macronutrient composition, physical activity, sleep, and stress. Personalizing diet based on CYP2C19 is not evidence-based. The clinical utility of CYP2C19 remains in pharmacogenetics (drug dosing), not weight management. For evidence-based nutrigenetics, consider validated markers like FTO or MC4R, but always within a comprehensive lifestyle approach.